Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Frontline TKI Selection

Authored by Talha Badar, published on 2026-11-07 09:11:55.0

The algorithm is broadly aligned with contemporary CML practice by integrating comorbidities, ELTS risk, toxicity profiles, response goals, and treatment-free remission priorities into frontline TKI selection. It appropriately includes imatinib, second-generation TKIs, and asciminib. The framework is simplified, however, and evidence for reduced-dose second-generation TKIs in frail patients and long-term survival or TFR outcomes with frontline asciminib remains less mature.

  1. Patient assessment
    Assess: Age Comorbidities Functional status Life expectancy Cardiovascular and metabolic risk Pulmonary history Renal and hepatic function Concomitant medications and potential drug interactions Treatment access and adherence considerations Clarify the treatment goal, including long-term disease control and whether achieving a deep molecular response with the possibility of future treatment-free remission (TFR) is an important priority.
    • Limited reserve
      Frailty and/or significant comorbidities. In patients with limited physiologic reserve, prioritize a frontline strategy that balances disease control with long-term tolerability and safety.
      • Lower-intensity strategy
        Consider: Imatinib Reduced-dose second-generation TKI in selected patients Asciminib Individualize selection according to comorbidities, tolerability, drug-specific toxicity, access, and patient priorities.
    • Good functional status
      • Assess disease risk
        Assess baseline disease risk using: ELTS — preferred Sokal score if used locally Risk scores help guide initial TKI intensity. Also consider the treatment goal: overall survival / durable disease control; rapid or deep molecular response; potential future treatment-free remission (TFR). High ELTS or intermediate-high Sokal risk favors consideration of a more potent upfront strategy.
        • Low-risk disease
          Goal-directed choice Deep molecular response / TFR goal → second-generation TKI or asciminib Safety / cost priority → imatinib Individualize according to comorbidities, expected toxicity, access, and patient preference.
        • Potent upfront therapy
          Consider: Second-generation TKI Asciminib A more potent frontline strategy may be favored in patients with higher-risk disease or when achieving a rapid/deep molecular response and potential future TFR is an important treatment goal. Select the specific agent according to comorbidities, toxicity profile, access, and patient preference.
  2. Key principle
    Overall survival is excellent with all frontline TKIs. Selection is driven by toxicity profile, response kinetics, comorbidities, treatment goals, and patient priorities.
tosprivacyApperley JF, Milojkovic D, Cross NCP, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797-1813. doi:10.1038/s41375-025-02664-w.US Food and Drug Administration. FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia. October 29, 2024.Hochhaus A, Wang J, Kim DW, et al; ASC4FIRST Investigators. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885-898. doi:10.1056/NEJMoa2400858.Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C, et al. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2021;193(2):346-355. doi:10.1111/bjh.17286.Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, et al. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Am J Hematol. 2022;97(11):1413-1418. doi:10.1002/ajh.26689.Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8(12):e902-e911. doi:10.1016/S2352-3026(21)00333-1.Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34:2138-2149. doi:10.1038/s41375-020-0931-9.Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333-2340. doi:10.1200/JCO.2015.64.8899.Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440-453. doi:10.1038/s41375-020-01111-2.Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Am J Hematol. 2022;97:894-904.